Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

Videos

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options. 

Haifaa Abdulhaq, MD, an associate clinical professor in Hematology and Oncology at the University of California, San Francisco (UCSF) and the director of hematology and the Hematology/Oncology Fellowship Program at UCSF Fresno, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma (DLBCL).

There is something to be said about the safety profile of tafasitamab and how it helps patients maintain quality of life, says Abdulhaq. Patients who have relapsed/refractory DLBCL and are transplant ineligible, are often older or have comorbidities. In this patient population, maintaining a balance between efficacy and a reasonable toxicity profile is essential, according to Abdulhaql; this is a benefit provided with tafasitamab. Lenalidomide (Revlimid) is another important chemotherapy-free, oral agent that provides value to these patients, concludes Abdulhaq.

Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.

Haifaa Abdulhaq, MD

Articles

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

Dr. Abdulhaq on the Benefits of Chemotherapy-Free Options in DLBCL